XNASALEC
Market cap167mUSD
Jan 17, Last price
1.71USD
1D
1.79%
1Q
-65.73%
IPO
-89.51%
Name
Alector Inc
Chart & Performance
P/E
—
P/S
1.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.14%
Rev. gr., 5y
28.52%
Revenues
97m
-27.36%
Net income
-130m
L-2.19%
CFO
-184m
L+805.91%
Earnings
Feb 25, 2025
Profile
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 97,062 -27.36% | 133,617 -35.48% | ||||||
Cost of revenue | 440,917 | 279,923 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (343,855) | (146,306) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 5,212 | 3,254 | ||||||
Tax Rate | ||||||||
NOPAT | (349,067) | (149,560) | ||||||
Net income | (130,391) -2.19% | (133,310) 375.87% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,550 | 4,514 | ||||||
BB yield | -0.38% | -0.59% | ||||||
| Debt | ||||||||
Debt current | 16,924 | 8,059 | ||||||
Long-term debt | 69,374 | 78,595 | ||||||
Deferred revenue | 210,845 | 491,601 | ||||||
Other long-term liabilities | 68,420 | 759 | ||||||
Net debt | (462,563) | (627,669) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (184,162) | (20,329) | ||||||
CAPEX | (2,381) | (4,117) | ||||||
Cash from investing activities | 101,918 | (159,014) | ||||||
Cash from financing activities | 2,550 | 4,514 | ||||||
FCF | (342,791) | (144,993) | ||||||
| Balance | ||||||||
Cash | 548,861 | 712,851 | ||||||
Long term investments | 1,472 | |||||||
Excess cash | 544,008 | 707,642 | ||||||
Stockholders' equity | (709,886) | (584,254) | ||||||
Invested Capital | 1,170,689 | 1,334,383 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 83,734 | 82,468 | ||||||
Price | 7.98 -13.54% | 9.23 -55.30% | ||||||
Market cap | 668,195 -12.22% | 761,176 -54.16% | ||||||
EV | 205,632 | 133,507 | ||||||
EBITDA | (335,007) | (137,834) | ||||||
EV/EBITDA | ||||||||
Interest | 16,250 | |||||||
Interest/NOPBT | ||||||||